Carbonic Anhydrase II (CA2) Rabbit Polyclonal Antibody

CAT#: TA323747

Anti-CA2 Rabbit Polyclonal Antibody

Size: 25 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,999.00

CNY 3,280.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (4)
Transient overexpression lysate of carbonic anhydrase II (CA2)
    • 100 ug

CNY 3,080.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human carbonic anhydrase II (CA2), 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Recombinant protein of human carbonic anhydrase II (CA2), 100 µg
    • 100 ug

CNY 9,998.00

Specifications

Product Data
Applications IHC, WB
Recommend Dilution WB: 1000-5000
WB positive control: Mouse brain tissue
IHC: 25-100
Positive control: Human colon cancer
Predicted cell location: Cytoplasm, Nucleus
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Immunogen Full length fusion protein
Formulation PBS pH7.3, 0.05% NaN3, 50% glycerol
Concentration lot specific
Purification Antigen affinity purification
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 29 kDa
Gene Name carbonic anhydrase 2
Background CA2 is one of several (at least 7) isozymes of carbonic anhydrase. Carbonic anhydrase catalyzes reversible hydration of carbon dioxide. Defects in this enzyme are associated with osteopetrosis and renal tubular acidosis. Essential for bone resorption and osteoclast differentiation By similarity. Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye.
Synonyms CA-II; CAC; CAII; Car2; HEL-76; HEL-S-282
Reference Data
Protein Families Druggable Genome
Protein Pathways Nitrogen metabolism
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...